高原地区神经重症患者急性肾损伤的临床特征及其对预后的影响
该回顾性研究纳入西藏自治区人民医院重症医学科2022年1月1日至2024年2月29日收治的390例成人神经重症患者,按KDIGO血肌酐标准诊断AKI。AKI发生率为21.3%(83/390),漏诊率50.6%(42/83),其中2-3期占49.4%(41/83),83.1%的AKI发生在入ICU后3天内。院内不良结局(死亡或放弃治疗)患者AKI患病率显著高于预后良好者(40.2% vs. 14.6%,P<0.05),多因素Logistic回归显示AKI为院内不良结局独立危险因素(OR=3.037,95%CI 1.724-5.351,P<0.001),且风险随AKI分期加重而升高。AKI患者ICU住院时间更长、住院费用更高、出院时肾功能持续恶化比例更高。
要点
- 高原神经重症患者AKI发生率为21.3%(83/390),漏诊率达50.6%(42/83),需提高对AKI的识别。
- 83.1%的AKI发生在入ICU后3天内,以早期发生为主,入ICU早期应密切监测肾功能。
- AKI为院内不良结局(死亡或放弃治疗)独立危险因素(OR=3.037,95%CI 1.724-5.351,P<0.001)。
- AKI分期越重不良结局风险越高:1期OR=2.734(95%CI 1.313-5.693),2-3期OR=3.408(95%CI 1.609-7.218)。
- AKI患者ICU住院时间更长[14(8,22)d vs. 11(5,16)d]、住院费用更高、出院时肾功能持续恶化率更高(27.7% vs. 2.3%)。
适用人群与场景
- 高原地区成人危重神经系统疾病患者,收治于重症医学科(ICU)。
- 研究为单中心回顾性分析,纳入西藏自治区人民医院重症医学科2022年1月1日至2024年2月29日收治的患者。
诊断标准与关键阈值
- AKI诊断依据KDIGO血肌酐标准。
- AKI分期:1期42例(50.6%)、2期21例(25.3%)、3期20例(24.1%),2-3期为中重度AKI。
- 主要终点为院内不良结局,定义为住院期间死亡或放弃治疗。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 院内不良结局(死亡或放弃治疗)患者AKI患病率显著更高(40.2% vs. 14.6%,P<0.05),AKI提示预后不良。
- AKI分期越重不良结局发生率越高:1期42.9%(18/42)、2期47.6%(10/21)、3期65.0%(13/20)。
- AKI患者出院时肾功能持续恶化率更高(27.7% vs. 2.3%),需关注出院时肾功能状态。
研究设计与关键结果
- 研究类型:单中心回顾性分析;样本量390例成人神经重症患者。
- AKI发生率21.3%(83/390),漏诊率50.6%(42/83);2-3期占49.4%(41/83);83.1%的AKI发生在入ICU后3天内。
- 住院期间102例发生不良结局,包括65例死亡和37例放弃治疗。
- 多因素Logistic回归:AKI为院内不良结局独立危险因素(OR=3.037,95%CI 1.724-5.351,P<0.001)。
- 按AKI分期:1期OR=2.734(95%CI 1.313-5.693,P=0.007);2-3期OR=3.408(95%CI 1.609-7.218,P=0.001)。
- AKI组vs非AKI组:ICU住院时间14(8,22)d vs. 11(5,16)d,住院费用14.85(8.88,23.41)万元 vs. 11.94(7.03,16.91)万元,出院时肾功能持续恶化率27.7% vs. 2.3%,差异均有统计学意义(均P<0.05)。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:单中心、回顾性设计,仅依据KDIGO血肌酐标准诊断AKI(未提及尿量标准),可能存在漏诊与选择偏倚;结论需前瞻性研究验证。
对床旁实践的改变
- 高原神经重症患者入ICU早期(尤其前3天)应主动筛查AKI,避免因漏诊率高(50.6%)而延误识别。
- AKI分期越重院内不良结局风险越高,可将AKI分期作为预后评估与病情沟通的参考指标。
- 原文未提及具体治疗干预措施,不能据此改变AKI处理方案。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the incidence and severity of acute kidney injury (AKI) in neurocritical patients at high altitude and its impact on prognosis.
METHODS: A retrospective analysis was conducted. The clinical data of adult critically ill neurological patients admitted to the critical care medicine of People's Hospital of Xizang Autonomous Region from January 1, 2022, to February 29, 2024 were enrolled. AKI was diagnosed according to the Kidney Disease: Improving Global Outcomes (KDIGO) serum creatinine criteria. The incidence, underdiagnosis rate and severity of AKI within 7 days after intensive care unit (ICU) admission were analyzed. The primary endpoint was in-hospital adverse outcome, defined as death or withdrawal of treatment during hospitalization. The secondary endpoint included persistent deterioration of renal function at discharge, length of ICU stay, total hospital stay and hospitalization costs. Univariate and multivariate Logistic regression analyses were performed to examine the relationship between AKI and adverse outcomes in patients with neurocritical illness.
RESULTS: Among the 390 critically ill neurological patients at high altitude, the incidence of AKI was 21.3% (83/390), with an underdiagnosis rate of 50.6% (42/83). Among the 83 patients with AKI, 42 (50.6%) had stage 1 AKI, 21 (25.3%) stage 2, and 20 (24.1%) stage 3; moderate to severe AKI (stage 2-3) accounted for 49.4% (41/83). In addition, most AKI cases (83.1%) developed within 3 days after ICU admission. During hospitalization, 102 patients experienced adverse outcomes, including 65 deaths and 37 cases of treatment withdrawal. The prevalence of AKI was significantly higher in patients with in-hospital adverse outcome than that in patients with favorable prognosis (40.2% vs. 14.6%, P<0.05). Multivariate Logistic regression analysis demonstrated that AKI was an independent risk factor for in-hospital adverse outcome in neurocritical patients at high altitude [odds ratio (OR)=3.037, 95% confidence interval (95%CI) was 1.724-5.351, P<0.001]. After multivariate adjustment, the risk of adverse outcomes increased with the severity of AKI (stage 1 AKI: OR=2.734, 95%CI was 1.313-5.693, P=0.007; stage 2-3 AKI: OR=3.408, 95%CI was 1.609-7.218, P=0.001). The incidence of adverse outcome increased progressively with the aggravation of AKI severity, which was 42.9% (18/42) in stage 1, 47.6% (10/21) in stage 2, and 65.0% (13/20) in stage 3. In addition, compared with non-AKI patients, AKI patients had longer length of ICU stay [days: 14 (8, 22) vs. 11 (5, 16)], higher hospitalization costs [ten thousand yuan: 14.85 (8.88, 23.41) vs. 11.94 (7.03, 16.91)], and a higher rate of persistent renal function deterioration at discharge (27.7% vs. 2.3%), with all differences being statistically significant (all P<0.05).
CONCLUSIONS: AKI exhibits a high incidence and common underdiagnosis in patients with high-altitude critical neurological illness. It mainly occurs at the early stage of ICU admission, with a high proportion of stage 2-3 cases. AKI is an independent risk factor for in-hospital adverse outcomes in such patients, and the risk of adverse outcomes increases with the severity of AKI stage.
参考来源
- Danzeng Q, Cai X, Lin Z, et al. [Clinical characteristics and impact on prognosis of acute kidney injury in neurocritical patients in high-altitude areas]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42693971. doi:10.3760/cma.j.cn121430-20260209-00082
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。